Navigation Links
Sorrento Therapeutics Announces Reverse Split of Common Stock
Date:8/1/2013

SAN DIEGO, Aug. 1, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) announced today that it has filed a Certificate of Amendment to its Restated Certificate of Incorporation to effect a 1-for-25 reverse stock split of its common stock, effective on July 30, 2013.  The proposal to effect a reverse stock split was approved by the Company`s stockholders at its Special Meeting of Stockholders held on April 26, 2013, and the specific 1-for-25 ratio was subsequently approved by the Company`s Board of Directors.

At the effective time of the reverse stock split, every twenty five shares of the Company`s issued and outstanding common stock will be automatically converted into one issued and outstanding share of common stock, without any change in par value per share. The reverse stock split will affect all shares of the Company`s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company`s equity incentive plans.  In addition, the reverse stock split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options or warrants outstanding immediately prior to the effectiveness of the reverse stock split. No fractional shares will be issued as a result of the reverse stock split.  The Company`s common stock will begin trading on the OTC QB on a split-adjusted basis when the market opens on Thursday, August 1, 2013.  The new CUSIP number for the Company`s common stock following the reverse stock split is 83587F 202.

The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 336.4 million to approximately 13.5 million.  

The Company has submitted a listing application to the The NASDAQ Capital Market. The Company's ability to become listed on The NASDAQ Cap
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit
2. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
3. Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development
4. Pain Management Therapeutics Market is Expected to Decline to USD 29.47 Billion Globally by 2018: Transparency Market Research
5. Global Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline: MarketResearchReports.Biz
6. United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
7. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
8. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
9. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
10. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
11. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global Human Albumin Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The human albumin market analysis is provided ...
(Date:9/18/2014)... 2014  U.S. biotech company Kultevat has ... for technology developed by the Donald Danforth Plant ... including for applications in production of natural rubber in ... was developed under the direction of Roger Beachy ... president of the Danforth Plant Science Center, and is ...
(Date:9/18/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... underwritten offerings of 10,000,000 shares of its Common Stock ... share, for expected gross proceeds of $20 million and ... at a price to the public of $2,000.00 per ... share of Series A Convertible Preferred Stock is non-voting ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
...   Sigma-Aldrich Corporation (NASDAQ: ... announced it has signed an agreement to acquire BioReliance Holdings, ... Avista Capital Partners for $350 million in cash.  The acquisition ... is expected to close in the first quarter of 2012.  ...
... According to a new market research report, ... , published by MarketsandMarkets ( http://www.marketsandmarkets.com ), global seed ... protection market. This growth is fueled by government encouragement ... This growth is particularly higher in geographies such as ...
... GENEVA, Jan. 9, 2012   Selexis SA announced ... Vice President of Strategic and Market Development. ... CEO, Dr. Igor Fisch and will be responsible for ... biologics and difficult-to-express protein markets. ...
Cached Biology Technology:Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 2Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 3Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 4MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016 2MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016 3Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development 2
(Date:9/17/2014)... health care to reproductive technologies, the justice and ... of people to identify key issues, articulate their ... find the most defensible ways forward. But what ... societal conversations?, The Hastings Center and the Presidential ... teamed up to publish a series of essays ...
(Date:9/17/2014)... Fauna Europaea started in 2000 as an EC-FP5 four-year ... years of steady progress and successful participations in several ... European Biodiversity Observation Network project (EU BON), to ... the contributors and to extend the general dissemination of ... Journal has applied its novel e-Publishing tools ...
(Date:9/17/2014)... research from the Copenhagen Centre for Social Evolution and ... theory that birth weight and -length can partially predict ... such as autism and schizophrenia later in life. The ... and subsequent hospital diagnoses for up to 30 years, ... The study is published today in the Proceedings ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3
... transcription the process inside the nucleus of cells by ... a large, ever-changing multiprotein complex is enlisted to assist ... an exquisitely choreographed dance, each step in the process has ... to be accurate and useful in subsequent events. These ...
... discovery by Canada-U.S. biophysicists will improve the understanding of ion ... which when they malfunction can cause genetic illnesses that attack ... As reported in the current issue of the Proceedings ... researchers from the Universit de Montral and the University of ...
... we maximise the value and use of epidemiological ... the theme of a conference being held on ... Co-organised by PHOEBE (Promoting Harmonisation of Epidemiological Biobanks), ... (Biobanking and Biomolecular Resources Research Infrastructure), the conference ...
Cached Biology News:CSHL scientists discover new way in which ubiquitin modifies transcriptional machinery 2Researchers advance knowledge of little 'nano-machines' in our body 2Harmonizing Biobank Research Conference in 2009 2Harmonizing Biobank Research Conference in 2009 3
Request Info...
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
...
Biology Products: